Multiple Sclerosis Susceptibility Genes: Associations with Relapse Severity and Recovery

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Mowry, Ellen M ^a   Carey, Robert F ^b   Blasco, Maria R ^c   Pelletier, Jean ^d   Duquette, Pierre ^e   Villoslada, Pablo ^f   Malikova, Irina ^d   Roger, Elaine ^e   Kinkel, R Phillip ^g   McDonald, Jamie ^b   Bacchetti, Peter ^h   Waubant, Emmanuelle ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d TIMONE HOSPITAL   (France)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD6 ANTIGEN; HLA DRB1 ANTIGEN; INTERLEUKIN 7 RECEPTOR;

ADULT; ALLELE; ARTICLE; CD6 GENE; CONTROLLED STUDY; DISEASE SEVERITY; EVI5 GENE; FEMALE; GENE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GPC5 GENE; HLA DRB1 GENE; HUMAN; IL7R GENE; MAJOR CLINICAL STUDY; MALE; MPHOSPH9 GENE; MULTIPLE SCLEROSIS; RGS1 GENE; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TNFRSF1A GENE;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLYPICANS; HLA-DRB1 CHAINS; HUMANS; MALE; MULTIPLE SCLEROSIS; PHOSPHOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RGS PROTEINS; YOUNG ADULT;

EID: 84885350502     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075416     Document Type: Article

References (31)

1. Mowry EM, Pesic M, Grimes B, Deen S, Bacchetti P, et al. (2009) Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology 72: 602-608.
2. International Multiple Sclerosis Genetics Consortium, (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357: 851-862.
3. International Multiple Sclerosis Genetics Consortium, (2010) Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. Hum Mol Gen 19: 953-962.
4. DeJager PL, Baecher-Allan C, Maier LM, Arthur AT, Ottoboni L, et al. (2009) The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A 106: 5264-5269.
5. Ban M, Goris A, Lorentzen AR, Baker A, Mihalova T, et al. (2009) Replication analysis identifies TYK2 as a multiple sclerosis susceptibility gene. Eur J Hum Genet 17: 1309-1013.
6. DeJager PL, Jia X, Wang J, deBakker PI, Ottoboni L, et al. (2009) Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 41: 776-782.
7. Australia and New Zealand Multiple Sclerosis Genetics Consortium, (2009) Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 41: 824-828.
8. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, et al. (2009) Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 18: 767-778.
9. Johnson BA, Wang J, Taylor EM, Caillier SJ, Herbert J, et al. (2010) Multiple sclerosis susceptibility alleles in African Americans. Genes Immun 11: 343-350.
10. Hoppenbrouwers IA, Aulchenko YS, Janssens AC, Ramagopalan SV, Broer L, et al. (2009) Replication of CD58 and CLEC16 as genome-wide significant risk genes for multiple sclerosis. J Hum Genet 54: 676-680.
11. International Multiple Sclerosis Genetics Consortium, (2009) The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun 10: 11-14.
12. International Multiple Sclerosis Genetics Consortium, (2010) IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes Immun 11: 397-405.
13. Hoppenbrouwers IA, Aulchenko YS, Ebers GC, Ramagopalan SV, Oostra BA, et al. (2008) EVI5 is a risk gene for multiple sclerosis. Genes Immun 2008 9: 334-337.
14. Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, et al. (2012) Randomized controlled trial of atorvastatin in CIS: the STAyCIS study. Neurology 78: 1171-1178.
15. Marcus JF, Spain RI, McDonald J, Julian LJ, Okuda DT, et al. (2010) Baseline data and rationale for study of riluzole for neuroprotection in early relapsing remitting multiple sclerosis. Mult Scler 16: 1004.
16. Confavreux C, (1994) Establishment and use of multiple sclerosis registers-EDMUS. Ann Neurol 36: S136-139.
17. Toledo J, Sepulcre J, Salinas-Alaman A, Garcia-Layana A, Murie-Fernandez M, et al. (2008) Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Mult Scler 14: 906-912.
18. Optic Neuritis Study Group (1991) The clinical profile of optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 109;1673-1678.
19. Beck RW, Clearly PA, Anderson MM, Keltner JL, Shults WT, et al. (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326: 581-588.
20. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group. N Engl J Med 343: 898-904.
21. Kinkel RP, Kollman C, O′Connor P, Murray TJ, Simon J, et al. (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66: 678-684.
22. Mowry EM, Pesic M, Grimes B, Deen S, Bacchetti P, et al. (2009) Clinical predictors of early second event in patients with clinically isolated syndrome. J Neurol 256: 1061-1066.
23. Dennison L, Moss-Morris R, Chalder T, (2009) A review of psychological correlates of adjustment in patients with multiple sclerosis. Clin Psychol Rev 29: 141-153.
24. Waldron-Perrine B, Rapport LJ, Ryan KA, Harper KT, (2009) Predictors of life satisfaction among caregivers of individuals with multiple sclerosis. Clin Neuropsychol 23: 462-478.
25. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, et al. (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214-219.
26. Kalincik T, Guttmann CR, Krasensky J, Vaneckova M, Lelkova P, et al. (2013) Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome. Genes Immun 14: 244-248.
27. Habek M, Brinar VV, Borovecki F (2010. Genes associated with multiple sclerosis: 15 and counting. Expert Rev Mol Diagn10: 857-861.
28. Tran T, Paz P, Velichko S, Cifrese J, Belur P, et al. (2010) Interferon β-1b induces the expression of RGS1 a negative regulator of G-protein signaling. Int J Cell Biol 2010: 529376.
29. Kofler DM, Severson CA, Mousissian N, DeJager PL, Hafler DA, (2011) The CD6 multiple sclerosis susceptibility allele is associated with alterations in CD4+ T cell proliferation. J Immunol 187: 3286-2391.
30. Sharrack B, Hughes RA, Soudain S, Dunn G, (1999) The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 122: 141-159.
31. Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, et al. (2004) Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult Scler 10: 41-46.